Amneal Pharmaceuticals, Inc. AMRX
Set alert
At close · Oct 30
After hours · Oct 30, 4:58 PM ET
- YTD
- +70.71%
- 1 year
- +115.10%
- Open
- 21.44
- Prev close
- 21.35
- Mkt cap
- 7.49B
- Vol
- 2.77M
- Avg vol
- 2.82M
- EPS
- 0.49
- P/E
- 43.90
- Div yield
- 0.00%
More statistics
- Low
- 21.27
- High
- 21.68
- Forward P/E
- 17.73
- Beta
- 1.22
- Short ratio
- 3.80
- Inst. own
- 48.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 19.05
- 200-d avg
- 15.70
- 1y target
- 23.43
News
4 days ago zacks.com
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago zacks.com
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
4 days ago zacks.com
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
5 days ago defenseworld.net
30,437 Shares of Amneal Pharmaceuticals, Inc. $AMRX Bought by Gibbs Wealth Management
Gibbs Wealth Management bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) during the third quarter, according to the company in its most recent 13F filing with the…
5 days ago zacks.com
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
-
1 week ago benzinga.com
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.
2 weeks ago defenseworld.net
Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX)
Amneal Pharmaceuticals (NASDAQ: AMRX - Get Free Report) and Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
3 weeks ago fool.com
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
3 weeks ago globenewswire.com
Amneal to Report Third Quarter 2026 Results on November 3, 2026
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on…
1 month ago gurufocus.com
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50
On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3.7% to $20.50, reflecting strong price performance especially in the context of its 52-wee
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27
Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.
1 month ago globenewswire.com
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
1 month ago zacks.com
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
1 month ago benzinga.com
Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts made mixed price-target changes for LYFT, AMRX, JBHT, CRM, APPF, FLNC and CRWD.
-
1 month ago benzinga.com
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.
1 month ago gurufocus.com
Amneal Pharmaceuticals Inc (AMRX) Stock Down 3.3% but Still Overvalued -- GF Score: 59/100
On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23
Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.
-
1 month ago benzinga.com
Amneal Pharmaceuticals Files Prospectus Related To The Offer And Sale Of Up To 28,942,098 Shares of Class A Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1723128/000114036126035617/ny20081412x1_s3asr.htm
2 months ago zacks.com
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
-
2 months ago benzinga.com
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
2 months ago zacks.com
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
2 months ago businesswire.com
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation…
2 months ago zacks.com
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
2 months ago zacks.com
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
2 months ago zacks.com
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.
2 months ago zacks.com
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
2 months ago zacks.com
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our…
-
2 months ago benzinga.com
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
-
3 months ago benzinga.com
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B Est
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100…
-
3 months ago benzinga.com
Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate
Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. This is a 20 percent increase over earnings of…
3 months ago benzinga.com
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
4 months ago benzinga.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.
-
4 months ago benzinga.com
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
4 months ago benzinga.com
Top 3 Health Care Stocks That May Collapse This Quarter
3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, but positive price action for TGTX.
6 months ago benzinga.com
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
-
6 months ago benzinga.com
FDA Takes Step Forward on Testosterone Therapy for Men
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
-
8 months ago benzinga.com
Earnings Scheduled For February 27, 2026
Earnings Scheduled For February 27, 2026
1 year ago benzinga.com
Earnings Scheduled For October 30, 2025
Earnings Scheduled For October 30, 2025
-
1 year ago benzinga.com
Earnings Scheduled For February 28, 2025
Earnings Scheduled For February 28, 2025
-
2 years ago benzinga.com
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Earnings Scheduled For August 4, 2023
Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.
-
3 years ago benzinga.com
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 469 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 337 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 497 companies set new 52-week lows.